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PENILAIAN FARMAKOEPIDEMIOLOGI DAN KOS PENGURUSAN 
PENYAKIT ASMA DI PUSAT KESIHATAN UNIVERSITI SAINS MALAYSIA 
 
ABSTRAK 
 
            Asma adalah satu penyakit kronik yang memberi kesan kepada lebih 
kurang 5 hingga 20% penduduk dunia. Ia menyebabkan morbiditi dan mortaliti 
yang signifikan, mempengaruhi kualiti hidup dan menyebabkan bebanan 
ekonomi yang tinggi.  Objektif pertama kajian ini adalah untuk menilai aspek 
farmakoepidemiologi pengurusan penyakit asma dengan menilai corak 
penggunaan ubat penyakit asma dan keduanya, untuk menganggar kos 
perubatan langsung penyakit asma di Kampus Induk Universiti Sains Malaysia 
(USM). Data pesakit luar bagi tahun 2003 dan 2004 dengan preskripsi-
preskripsi mereka dikumpulkan secara retrospektif dari rekod perubatan 
elektronik.  Kaedah kajian penggunaan ubat dan kos penyakit digunakan dalam 
kajian ini.  Prosedur statistik inferensial yang digunakan termasuklah ujian-ujian 
Khi Kuasa Dua, Kruskal-Wallis, Mann-Whitney, Wilcoxon dan Student-t. Paras 
signifikan yang digunakan adalah 0.05 dengan selang keyakinan 95%. 
Terdapat seramai 205 orang pesakit asma pada tahun 2003 manakala 237 
orang pada tahun 2004.  Dapatan kajian menunjukkan kebanyakan pesakit 
adalah berbangsa Melayu, staf USM dan tangunggan. Kebanyakan pesakit 
adalah di dalam linkungan umur 1-12 serta 26-45 tahun. Dari segi penggunaan 
ubat, purata bilangan ubat per preskripsi adalah 2.1 bagi tahun 2003 dan 2.2 
bagi tahun 2004. Kajian ini menunjukkan agonis-β2, yang penggunannya 
meningkat secara langsung dengan umur pesakit, adalah ubat yang paling 
 xxi
banyak dipreskripsikan dan digunakan bagi tahun 2003 dan 2004. Ubat 
kortikosteroid inhalasi (ICS) adalah ubat kedua yang paling kerap 
dipreskripsikan. Seramai 23% dan 26.6% pesakit asma pada tahun 2003 dan 
2004 setiap satu mengambil ICS. Kombinasi ubat yang paling biasa 
dipreskripsikan adalah agonis-β2 + ICS. Kos min dan median preskripsi pada 
tahun 2003 ialah RM20.44±12.85 dan RM18.29, manakala pada tahun 2004 
kos min ialah  RM20.13±13.63  dan median sebanyak RM16.89.  Kos preskripsi 
dan kos ubat-ubatan per pesakit per tahun meningkat dengan umur pesakit. 
Terdapat perbezaan dalam kos preskripsi berdasarkan kategori pekerjaan dan 
pegawai perubatan.  Kajian ini mendapati penggunaan ubat asma meningkat 
daripada 1.305 DID pada tahun 2003 kepada 1.514 DID pada tahun 2004.  Dari 
segi kos perubatan langsung, 75% daripada kos tersebut bagi kedua-dua tahun 
2003 dan 2004 adalah untuk ubat, manakala peratus kos untuk personel 
kesihatan adalah 25% daripada jumlah keseluruhan kos perubatan langsung. 
Ubat asma memakan belanja 90% daripada kos total ubat-ubatan bagi tahun 
2003 dan 2004. Merujuk kepada ubat-ubat penyakit asma, agonis-β2 inhalasi 
terdiri daripada 61% manakala ICS terdiri 23% daripada kos total ubat-ubat bagi 
penyakit asma. Jumlah keseluruhan kos perubatan langsung bagi pengurusan 
asma bagi tahun 2003 adalah RM12,929.17 dan kos per pesakit per tahun 
adalah RM 63.07. Dalam tahun 2004, jumlah keseluruhan kos perubatan 
langsung meningkat kepada RM15,475.00 dan kos per pesakit per tahun 
meningkat kepada RM65.30.  Perbandingan data bagi tahun 2003 dan 2004 
menjelaskan bahawa tiada perbezaan yang signifikan dari segi profil 
demografik, corak mempreskripsi, kos purata preskripsi, purata lawatan per 
pesakit, purata bilangan ubat per perpreskripsi, penggunaan drug per 
 xxii
preskripsi, preskripsi ubat-ubatan per pesakit dan kos langsung per pesakit per 
tahun. 
Kata Kunci: Asma, penggunaan ubat, penilaian kos, Pusat Kesihatan, pesakit 
luar, farmakoepidemiologi, Universiti Sains Malaysia, universiti.  
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PHARMACOEPIDEMIOLOGIC AND COST EVALUATION OF ASTHMA 
MANAGEMENT IN UNIVERSITI SAINS MALAYSIA HEALTH CENTER 
 
ABSTRACT 
 
            Asthma is a chronic disease that affects about 5% to 20% of the world’s 
population causing significant morbidity and mortality, affecting the quality of 
life, and resulting in considerable economic burden. The first objective of the 
study is to evaluate the pharmacoepidemiology of asthma management by 
evaluating the pattern of anti-asthma drugs utilization and secondly, to estimate 
the direct medical costs of asthma in the main campus of Universiti Sains 
Malaysia.  Data of outpatients in 2003 and 2004 with their prescription records 
were collected retrospectively from electronic medical records. The drug 
utilization research and cost of illness methods were used in this study. The 
appropriate inferential statistics used include the Chi-square test, the Kruskal-
Wallis test, the Mann-Whitney test, Wilcoxon test, and the student t-test. The 
significance level was 0.05 with a confidence interval of 95%.  There were 205 
and 237 asthmatic patients in 2003 and 2004, respectively. The findings from 
this study showed that the majority of patients were Malays, USM’s staff 
members and dependants. Most of the patients were in the 1-12 and 26-45 age 
groups. In terms of drugs utilization, the mean drug per prescription was 2.1 in 
2003 and 2.2 in 2004. The study showed that β2-agonists, the use of which 
increased with age, were the most prescribed and consumed drug in 2003 and 
2004. The inhaled corticosteroid (ICS) was the second most frequently 
prescribed drug.  23.0% and 26.6 % of asthmatic patients in 2003 and 2004 
 xxiv
respectively took ICS. The most commonly anti-asthma combination prescribed 
was β2-agonist + ICS. The mean and median cost of prescription in 2003 was 
RM20.44±12.85 and RM18.29, while in 2004, the mean cost was 
RM20.13±13.63 with a median of RM16.89. The cost of prescriptions and the 
cost of drugs per patient per year increased with age. There were variations in 
the cost of prescription with regard to category of patients and prescribers.  The 
study found that the consumption of anti-asthma drugs increased from 1.305 
DID in 2003 to 1.514 DID in 2004. In terms of direct medical cost, drugs 
constituted about 75% of total direct medical costs in 2003 and 2004, while the 
cost of health personnel constituted 25% of total direct medical costs.  Anti-
asthma medications accounted for 90% of total drug costs in 2003 and 2004. 
With regard to anti-asthma drugs, inhaled β2-agonist accounted for 63% of total 
anti-asthma drugs cost in 2003 followed by ICS (18%). In 2004, inhaled β2-
agonist accounted for 61% while ICS accounted for 23% of total anti-asthma 
drug costs. The total direct medical cost of asthma management in 2003 was 
RM12,929.17 and the cost per patient per year was RM 63.07. In 2004, the total 
direct medical cost increased to RM15,475.00 and the cost per patient per year 
increased to RM65.30. A comparison of the data for 2003 and 2004 revealed 
that there was no significant difference in terms of demographic profile, 
prescribing patterns, the average cost of prescriptions, the average visit per 
patient, the average number of drugs per prescription, the consumption of drugs 
per prescription, the prescription of drugs per patient, and direct cost per patient 
per year.  
Keywords: Asthma, cost evaluation, drug utilization, Health Center, outpatient, 
pharmacoepidemiology, Universiti Sains Malaysia, university. 
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CHAPTER 1 
 
INTRODUCTION 
 
1.1      Background 
             According to Evans (1998) and the National Heart, Lung and Blood 
Institute (NHLBI) and World Health Organization (WHO) (1995) reports, asthma 
is a chronic respiratory disease that affects 5-20% of the world population and 
can cause significant morbidity and mortality. People of all ages especially 
children are affected by asthma. It can be a severe and sometimes fatal disease 
(NHLBI and WHO, 1995). Asthma affects the quality of life and leads to 
considerable restrictions on physical, emotional and social activities. Asthma 
can be significant burden not only in terms of health care costs, but also in 
terms of lost productivity and reduced participation in family life (Ungar et al., 
2000; NHLBI and WHO, 1995). Asthma also interferes with schooling and work, 
as it can lead to absenteeism among children and lost workdays among adults 
as well as premature retirement (Clark, 1998). 
             Evidence suggests that the prevalence of asthma around the world is 
increasing. This ranges from a 50% increase in New Zealand to a 150% 
increase in Scotland (Palatine and Sly, 1999). The prevalence of asthma among 
Malaysian children has been reported to be around 4.9-13.8% (Azizi, 1990; 
Quah et al., 1997). The national prevalence of asthma symptoms in children 
range widely from 1.6% in Indonesia to 36.8% in UK (Beasley et al., 1998). 
However, in Saudi Arabia, it has been found to be 7% to 10% among school 
children (AL-Frayh, 1990; AL-Rayes et al., 1997). A National Health Interview 
survey conducted in 1995 in the United States indicated that 15 million 
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individuals identified themselves as asthmatic, with approximately 5 million 
being under the age of 20 (Benson and Marrano, 1998). In the United States, 
asthma was the most common chronic illness in children (Kelly and Kamada, 
1998).  
             The increasing of frequency of the asthma coupled with its under 
diagnosis, its inadequate, inappropriate treatment and the non-adherence to 
asthma medication prescriptions are considered to be the major factors for 
deaths and morbidity among asthmatic patients. In addition, asthma consumes 
high medical care resources (Ganse et al., 2002; Eason and Markowe, 1987; 
Suissa et al., 2002; Suissa et al., 2000; Halterman et al., 2000; Barnes, 1994; 
British Thoracic Association, 1982). Asthma can lead to an increase in the 
socioeconomic burden of individuals suffering from it, as well as that of their 
families who share the cost. Society as a whole also bears the burden through 
the loss of economic productivity when patients are unable to work (de Marco et 
al., 2003; Clark, 1998). 
             Asthma can be alleviated through appropriate asthma management and 
prevention. The main approach towards the management of asthma is the use 
of effective treatments (pharmacologic managements), and avoidance of 
exposure to allergens and other triggers (non-pharmacologic management) 
(Busse, 1993; Svedmyr, 1997). In addition, education of both patients and 
health professionals is the key to the success of every asthma management 
and prevention efforts (Clark, 1998). Furthermore, an improved adherence to 
prescriptions of long-term control medications (such as inhaled corticosteroids) 
can lead to reduced morbidity, mortality, and consumption of health care 
resources (Neffen et al. 2006; Goldman et al., 2000; Momile et al., 1996; Schatz 
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et al., 2003). Additionally, it can also reduce the overuse of quick relief, or PRN 
(as needed) medications (Gottlieb et al, 1995). A study of parent-reported 
pediatric asthma medications use, noted an excessive reliance on PRN 
medications coupled with non-adherence to control drug prescriptions (Lozano 
et al., 2003).             
             Although the superiority of inhaled corticosteroids (ICS) for asthma 
control has been well established, these drugs used irregularly and underused 
(Staa, et al., 2003; de Marco et al., 2005; Anis et al., 2001). Prescribers often 
hesitate to prescribe ICS due to a fear of systemic side effects. In contrast, 
patients usually discontinued the use of ICS due to expectations of immediate 
symptom relief (Anzueto and Angel, 2000). Under treatment of asthma has 
been reported as a problem in several European countries and in the United 
States (Kuar et al., 1998; Bousquet et al., 1996; Adams et al., 2002).  
             The economic impact of asthma is increasing, particularly in the second 
half of the 20th century in some countries, and represents a substantial burden 
on health care resources in these countries. Health care costs are under 
pressure in all countries, and decisions about the use of new medicines are not 
only concerned with safety and tolerability assessments, but also value for 
money (Barnes et al., 1996). Hence, it is important for professionals, health 
economists, and planners to work as a team to understand the costs of asthma 
in order to identify where the burden occurs, to assess the effectiveness of 
current asthma medications, and to know how to achieve optimal cost 
effectiveness.  
             When the economic burden of asthma is considered, the assessment of 
both direct costs (i.e., cost of providing health services) and indirect costs (i.e., 
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the value of the resources lost as a result of illness such as absenteeism from 
work and other daily activities) must be considered (Stempel, 2003; Barnes et 
al., 1996).    
             For effective asthma management and rational use of antiasthma 
drugs, it is important to have information on the previous pattern of the use of 
these drugs, whether health care professionals and public health officials are 
acting according to national asthma guidelines in asthma management, how 
much money was spent on asthma management, and where high expenditure 
occurs.  
 
1.2 Asthma 
             Asthma is a chronic inflammatory disease of airways, which causes 
significant morbidity and mortality if not managed optimally. The disease is 
associated with a range of symptoms, including cough particularly at night, 
wheezing, breathing difficulty and chest tightness. These episodes were 
reversible, either spontaneously or with treatment (NHLBI and WHO, 1995). 
    
1.2.1 Classification of asthma 
             Asthma is highly variable. It can be intermittent, mild persistent, 
moderate persistent, and severe persistent. The severity of asthma is 
determined by an assessment of symptoms, its clinical signs, and through 
measurements of respiratory function using tests such as peak expiratory flow 
rate (PEFR) or forced expiratory volume in 1 second (FEV1). The determination 
of asthma severity is very important in asthma treatment, as drug dosage can 
be determined based on the nature of the disease. In other words, therapy is 
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increased (step-up) as the severity of asthma increases and is reduced (step-
down) as asthma control is achieved (Global Initiative for Asthma (GINA) and 
NHLBI, 2005; Bennett and Brown, 2003). 
             Table 1.1 below shows the classification of asthma severity according 
to the frequency of its symptoms, and pulmonary function measurement as 
adapted from National Asthma Education and Prevention Program (NAEPP) 
(1997).  
 
Table 1.1: Classification of asthma severity according to frequency 
symptoms, and pulmonary function measurement as adapted from 
NAEPP (1997). 
Asthma 
severity 
Symptoms Nighttime  
symptoms  
Lung function 
Step 4 
Severe 
persistent 
*Continual symptoms 
*Limited physical activity
*Frequent exacerbation 
Frequent *FEV1 or PEF ≤ 60% 
predicted  
*PEF variability ≥ 30% 
 
Step 3 
Moderate 
persistent  
*Daily symptom 
*Daily use of inhaled 
short acting β2-agonist 
*Exacerbations affect 
activity 
 *Exacerbations  ≥ 2 
times a week 
 
≥ 2 times  a 
month 
*FEV1 or PEF > 60%- 
<80%  predicted 
*PEF variability > 30% 
Step 2 
Mild 
persistent 
*Symptoms > 2 times a 
week 
But <1 time a day 
*Exacerbations may 
affect activity 
 
> 2 times a 
month 
*FEV1 or PEF ≥ 80% 
predicted  
*PEF variability < 20% 
Step 1 
Intermittent 
*Symptoms ≤ 2 times a 
week 
*Asymptomatic and 
normal PEF between 
exacerbations 
*Exacerbations brief 
(from a few hours to a 
few days); intensity may 
vary  
   
≤ 2 times  a 
month 
*FEV1 or PEF ≥ 80% 
predicted  
*PEF variability < 20% 
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1.2.2 Approach of asthma management 
             There are a few approaches utilized in the management of asthma. In 
the following subsections, each of these approaches will be explained in detail. 
They are: 
• Patient and family members education: Patients must be 
knowledgeable about asthma and its treatments. Patients must learn 
how to take the prescribed medications correctly, to differentiate between 
quick relief and long-term preventive medications, to avoid the triggers of 
asthma, to be aware of the steps to follow if symptoms occur, to follow an 
asthma management plan, and to seek for medical care in order to 
prevent serious attacks (Gibson et al., 2003).  
• Avoidance of exposure to allergens and precipitating factors; a critical 
component of asthma control is the identification and management of 
allergens or “triggers” of asthma. This approach is appropriate for 
extrinsic asthma and may be feasible when it is related to some specific 
situation, e.g. occupational asthma, but it is less feasible if, it is 
widespread, e.g. house-dust mites (NHLBI and WHO, 1995).    
• Use effective medications; this measure includes the use of 
medications to reduce bronchial inflammation and hyperactivity, and 
dilatation of narrowed bronchi (GINA and NHLBI, 2005).   
 
1.2.3  Asthma treatment 
              An assessment of the disease’s severity is crucial in determining the 
optimal treatment. A wide range of different classes of medication are available 
for treatment of asthma and the selection of optimal treatment or combinations 
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of antiasthma medication is essential to ensure that the disease is well 
controlled. It has been suggested that the current trends toward increased 
morbidity and mortality associated with asthma may be due to under diagnosis, 
and under treatment of the disease (Barnes, 1994). In general, the treatment 
regimens should consist of quick relief medications for all patients, and long-
term control medications (anti-inflammatory drugs) for all patients with 
persistent symptoms i.e., steps 2 through 4 severities (GINA and NHLBI, 2005).  
 
1.2.3.1      Quick relief medications  
            These medications are used by all asthmatic patients. They are 
bronchodilator drugs, which relieve bronchospams and improve the symptoms 
of asthma. They should be used as required rather than regularly. The most 
common quick relief medications used are the short acting β2-agonists. In some 
cases, anticholinergic agents are used. They should be taken as required rather 
than regularly. They consist of three main groups: β2-agonists, anticholinergics 
and theophylline. 
 
1-          β2-agonists 
            These are the most effective bronchodilators with few side effects when 
taken by inhalation (NHLBI and WHO, 1995; Bennett and Brown, 2003; Tierney 
et al., 2005). Their main side effects are tremor and tachycardia. The short 
acting formulations β2-agonists (inhaled salbutamol and terbutaline) are used 
for acute exacerbations of asthma in addition to short β2-agonists tablet or 
syrup. In contrast, long acting inhaled formulations (salmeterol, and formoterol) 
are indicated for asthma prevention in combination with corticosteroids. 
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Sustained release oral formulations β2-agonists (salbutamol) are also available 
and may be used by patients who cannot use long acting inhaled β2-agonists 
(Tierney et al., 2005).   
 
2-         Anticholinergics drugs 
             Inhaled anticholinergics have a slower onset but a longer duration of 
action. They are frequently combined with β2-agonists in an urgent care setting. 
They have very few side effects, as they are poorly absorbed from the lung. The 
common side effects associated with inhaled anticholinergics are dry mouth, 
blurred vision, and urinary retention. An example of an inhaled anticholinergic is 
ipratropium bromide (Kelly and Sorkness, 2005; Walker and Edward, 2003)  
 
3-         Methylaxnthines (Theophylline)  
             The short acting theophylline may be used to treat moderate to severe 
attacks when high doses of inhaled β2-agonists, the preferred treatment, are not 
available (NHLBI and WHO, 1995; Kelly and Sorkness, 2005). The addition of 
short acting theophylline to inhaled β2-agonists does not provide any additional 
bronchodilator effect. On the other hands, long acting (sustained release) 
theophylline is indicated for asthma maintenance therapy in order to control 
asthma symptoms and to improve lung function. When inhaled corticosteroids 
and sodium cromoglycate are not available or are too costly, theophylline can 
be used as a long-term medication (Aracangello and Peterson, 2006; Tierney et 
al., 2005)     
            Theophylline appears to exert a weak bronchodilator and/ or an anti-
inflammatory effect. These drugs are found in oral and parenteral form and they 
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have a narrow therapeutic window (Kelly and Sorkness, 2005; Walker and 
Edward, 2003). At therapeutic serum level, theophylline can cause a variety of 
cardiac and central nervous system effects including palpitations, tachycardia, 
tremor, insomnia, headache, and irritability (Tierney et al., 2005). Because of its 
potentially serious side effects, theophylline is usually considered as only a third 
line agent for asthma management. Its sustained release form is useful in 
nocturnal asthma (Weinberger and Hendeles, 1983), (e.g. Nuelin SR, Theodur, 
and Euphylline.) 
 
1.2.3.2 Anti-inflammatory drugs  
             These drugs are used for patients with persistent asthma and they act 
by reversing and preventing inflammation caused by an asthma attack. These 
drugs include: 
 
1-        Corticosteroids  
           Corticosteroids are the main prophylactic drugs in adult asthmatics. They 
are indicated for both prevention and the treatment of asthma exacerbations. 
They should be taken in inhalation in minimum doses to reduce their side 
effects (Toogood, 1990). On the other hand, since an optimal response to ICS 
requires 4 weeks of therapy, the oral or parenteral routes may be used for 
severe chronic asthma exacerbation (Kelly and Kamada, 1998). Common oral 
corticosteroids include prednisolone and methylprednisolone, while examples of 
ICS include beclomethasone dipropionate, budesonide, and fluticasone. Study 
estimates suggest that compliance with inhaled corticosteroids is only about 34 
to 56% (Yuksel et al., 2000). ICS side effects are generally minor. The most 
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common side effects are dysphonia, cough, and oral candidiasis (Walker and 
Edward, 2003). These side effects are attributed to oropharyngeal depositions 
of the drug.  
 
2-        Sodium cromoglycate (Intal) 
           Sodium cromoglycate impairs the immediate response to allergen and 
acts by inhibiting the release of mediators from the mast cells (Kelly and 
Sorkness, 2005; Aracangello and Peterson, 2006). Cromoglycate is not 
effective at terminating an existing attack, i.e. it prevents bronchoconstriction 
rather than induces bronchodilation. It is administered by inhalation (well 
absorbed from the lungs, but poorly absorbed from gastrointestinal tract) and is 
very safe with no significant side effects. It is useful in extrinsic (allergic) and 
exercise-induced asthma (Bennett and Brown, 2003). 
            Nedocromil sodium is structurally unrelated to cromoglycate but has a 
similar profile of actions and can be used by metered aerosol in place of 
cromoglycate (Bennett and Brown, 2003).  
 
1.2.3.3 Other drugs 
             Antileukotrienes are bronchodilators that act by terminating the actions 
of leukotrienes. The NAEPP recommends that the antileukotrienes (zileuton, 
zafirlukast, and montelukast) should be considered as second or third line drugs 
for asthma control following β2-agonists and corticosteroids. Adverse effects of 
antileukotrienes are infrequent and mild including headache, dizziness, nausea, 
and diarrhea (GINA and NHLBI, 2005; Tierney et al., 2005)    
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             Ketotifen is a histamine H1-receptor blocker and also may have some 
antiasthma effect, but it has been proven to be of limited efficacy and benefit in 
many clinical trials. Similarly as with other antihistamines, it can cause 
drowsiness (Bennett and Brown, 2003). 
    
1.2.3.4 Stepwise approach to therapy and asthma guidelines 
             The appropriate management of asthma depends on an accurate 
assessment of asthma severity and the appropriate prescription of medications. 
In order to establish the proper management parameters, various sets of 
asthma guidelines, both national and international guidelines such as Global 
Initiative for Asthma (GINA), and the Malaysian consensus guidelines on the 
management of asthma (Malaysian Thoracic Society, 1996) have been issued 
over the last few years. These guidelines have been designed to help primary 
care physicians, GPs, nurses, public health officials, and program planners in 
the management of their patients, in order to reduce the personal, social, and 
economic burden of asthma. Though these asthma guidelines were published 
ten years ago and emphasize the use of ICS as the first line treatment for 
persistent asthma, the results of various studies suggested that the health 
professionals do not strictly adhere to them (Gourgoulianis et al., 1998; 
Vermeire et al., 2002; Poluzzi et al., 2002; Verleden and Vuyst, 2002; Donahue 
et al., 2000). Consequently, this problem leads to poor quality of life among 
patients, and a heavy social burden (de Macro et al., 2003). 
             Despite improvements in understanding asthma pathophysiology and 
the availability of effective drugs over the last decade, poor asthma control has 
led to an increase in asthma frequency and severity in many countries, both 
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among children and adults. There are two major reasons for the lack of success 
in the management of asthma. First, under prescribing of medications by 
doctors (Rabe et al., 2004; Adams et al., 2002; Cydulka et al., 2005), and 
second, the poor prescription compliance by patients (Cerveri et al., 1999). Poor 
compliance of patients can be overcome by patient education, more frequent 
patient contact, the development of a close patient-clinician partnership, and 
simplification of treatment (Bender, 2002; Stempel et al., 2005). 
             Because of variations in asthma severity among different patients, and 
within each patient over a period of time, a step approach to therapy is 
recommended to control asthma with the least possible use of medications 
(GINA and NHLBI, 2005; Tierney et al., 2005). The number and frequency of 
medications increase (step-up) as asthma worsens and decrease (step-down) 
when asthma is kept under control. After classifying the severity of a patient’s 
asthma, the physician or GPs should judge the treatment stage. Once control is 
sustained for about 3 months, a reduction in therapy or step-down can be 
considered. This helps to reduce the risk of side effects and enhances 
adherence to the treatment plan (NHLBI and WHO, 1995). The National Asthma 
Education and Prevention Program (NAEPP, 1997) has developed treatment 
recommendations specific to each severity level (please refer to Table 1.2). 
Among them are, patients should take a rapid acting bronchodilator, such as a 
short acting inhaled β2-agonist, for relieving asthma exacerbations regardless of 
the disease’s severity. Patients with mild intermittent asthma (Step 1) do not 
need daily maintenance medications since these patients have normal 
pulmonary function between attacks. However, if these patients are using their 
β2-agonists more than twice a week, a step-up in the treatment regimen is 
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needed. Patients with mild, moderate, and severe persistent asthma (Step 2, 3, 
and 4, respectively) require daily use of maintenance medications. Maintenance 
or “preventive” medications include ICS, oral steroids for severe asthma, 
theophylline, long acting β2-agonists (salmeterol, formoterol), mast cell 
stabilizers (cromolyn, nedocromil) and antileucotrienes ((GINA and NHLBI, 
2005; Tierney et al., 2005; Kelly and Sorkness, 2005). 
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Table 1.2: Stepwise and approach for managing asthma in adults and 
children over 5 years of age (Adapted from NAEPP, 1997)  
 
Asthma 
severity 
Long term management Quick-relief  for 
exacerbation 
Persistent-
severe 
Step (4) 
Daily medications: 
*Anti-inflammatory: High dose ICS (500-2000µg/ 
day or more, beclomethasone  equivalent)  
                                  + 
*Long acting bronchodilator-either long acting 
inhaled β2-agonist, theophylline SR or long acting 
β2-agonist 
                                   + 
*Corticosteroid tablets or syrup (2mg/ kg/ day, 
not to exceed 60mg/ day).  
 
Short  acting 
inhaled β2-gonist 
on PRN basis 
Persistent-
moderate 
Step (3) 
Daily medications: 
Anti-inflammatory: either 
*Medium dose ICS (500-800µg/day) 
beclomethasone equivalent 
                                     or 
*Low medium dose ICS 
                                 + 
*Long acting bronchodilator (long acting inhaled 
β2-agonist, theophylline SR or long acting  
β2-onist) 
If needed: 
*Medium high dose ICS (500-2000µg/day) or 
beclomethasone equivalent. 
                                     + 
*Long acting bronchodilator, specially for night 
symptoms (long acting inhaled β2-agonist, 
theophylline SR or long acting β2-agonist) 
  
Short  acting 
inhaled β2-gonist 
on PRN basis 
Persistent-mild 
Step (2) 
Daily medications: 
Anti-inflammatory: either 
*Low dose ICS  
                                     or 
*Cromolyn or nedocromil (usually chosen as the 
first line for children) 
Other alternatives:  
*Sustained –release theophylline (to serum level 
of 5 to 15µg/ ml; generally not preferred.  
                                    
*Antileukotrienes may be also considered for 
patents ≥12 years old; however, the exact place 
of antileukotrienes in therapy has not been firmly 
established. 
 
Short  acting 
inhaled β2-gonist 
on PRN basis 
Intermittent-
mild 
Step (1) 
Daily medications: 
None needed 
 
Short  acting 
inhaled β2-gonist 
on PRN basis 
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1.3   Asthma in Malaysia 
 
             A National Health and Morbidity Survey in 1996 indicated that the 
prevalence of asthma in Malaysia was 4.2%. The survey also shows that the 
prevalence of asthma varied according to the socioeconomic status of the 
patients, and the geographical area. The study found that asthma was high 
among lower socioeconomic groups (low education and income levels), and in 
rural areas. By ethnicity, Chinese have a lower prevalence of asthma than the 
other races. In terms of age, the study found that the prevalence of asthma 
decreased by age but increased again after 40 years and above. The survey 
finding also revealed that the majority of asthma cases was categorized as mild 
(87.3%), followed by moderate (9.9%). Only 2.7% of the asthma patients 
surveyed had severe asthma. The study also found that the majority of mild 
asthma (65%) and moderate asthma cases (52%) were on non-inhaler 
treatment. The similar survey revealed that there was inadequate treatment and 
monitoring of asthmatic patients especially those with severe cases of asthma. 
This eventually leads to high expenditure in health care costs (Rugayah et al., 
1999). 
 
1.4  Asthma in the USM Health Center  
 
             Data obtained from USM’s Health-Care Report indicates that, asthma 
ranked second after hypertension among chronic diseases in USM’s Main 
Campus in 2001 and 2002 (Izham, 2003). There were 238 asthmatic patients in 
2001 and 237 in 2002. Table 1.3 shows the number of patients with different 
chronic diseases. 
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Table 1.3: Number of patients visiting the USM Health Center during 2001 
and 2002 with different chronic diseases*  
 
Disease Patients  
number 
(2001) 
Patients 
number 
(2002) 
Increase 
rate (%) 
 
Hypertension 374 449 20.1 
Asthma 238 237 -0.4 
Diabetes 175 208 18.9 
Other (circulatory problem) 
 
  39  18 -53.8 
Ischemic heart disease   27 40 48.1 
TB     7    3 -57.1 
Total 860 955 11.0 
*Source: USM’s Health-Care Report (Izham, 2003) 
 
 
1.5 Pharmacoepidemiology 
             In order to choose an appropriate disease management regime and to 
obtain the rational use of drugs, it is important to have information on the past 
and present use of drugs. This information must be concerned with types of 
drugs prescribed, to which patient they were prescribed and indications on their 
use. In addition, it is important to know the therapeutic cost/ benefit of drug use. 
This is because without knowledge of how a drug is actually used, it is 
impossible to discuss what correct or incorrect therapy is, or suggests 
measures to improve prescribing habits, or initiate a discussion on rational drug 
use. This information must be made available in drug utilization statistics for the 
ultimate result. This information will help to assess whether the drug is being 
rationally used or not (Nordic Council on Medicines, 1990; WHO, 2003). This 
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can be achieved by applying pharmacoepidemiology methods. WHO defined it 
as “the study of the clinical use of drugs in populations or the study of the use 
and effects/ side-effects of drugs in large numbers of people with the purpose of 
supporting the rational and cost-effective use of drugs in the population, thereby 
improving health outcomes” (WHO, 2003).  
 
1.6 Drug Utilization  
             Drug utilization (DU) is essential part of pharmacoepidemiology and 
they are some times used interchangeably (WHO, 2003). DU was defined by 
WHO as “the studies of marketing, distribution, prescribing, and use of drugs in 
society, with special emphasis on resulting medical, social and economic 
consequences”. DU can be divided into descriptive and analytical studies. The  
descriptive studies describe the patterns of drug utilization and identify 
problems that need more studies, while analytical studies try to link data on 
drug utilization and figure on morbidity with the outcome of treatments and the 
quality of care with aims of assessing whether drug therapy is rational or not. 
The WHO defines the rational use of drug as each patient receiving medication 
appropriate for their clinical needs, at an optimal dose, for an adequate period, 
with minimum costs to them and the community. 
             Drug utilization data provide indispensable information on drug 
prescription and can be used to:   
• describe patterns of the drug’s use 
• look at the development  of therapeutic profiles 
• estimate the number of patients exposed to various drugs 
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•    measure the effects of educational, informative, regulatory efforts, 
price policies, and reimbursement schemes, etc. 
• define areas for further investigations on the efficacy and safety of                     
.     drug therapy. 
• indicate over-use, under-use, misuse, and abuse of drugs. 
• estimate drug need in a society (related to morbidity pattern) to be 
used as a bases for the planning of drug selection, supply, and 
distribution.  
   
1.6.1 Units of measurement in drug utilization studies  
             In order to measure drugs use, it is important to have both a 
classification system and a unit measurement. To study drug use over time, it is 
important to have a stable and consistent method, which makes it possible to 
compare drug statistics both nationally and internationally (WHO Collaborating 
Centre for Drug Statistics Methodology, 2005). There are many different ways 
of expressing drug consumption (cost, volume measures, prescribed daily dose 
(PDD), and defined daily dose). None of these measures alone gives a 
complete picture of drug utilization, but if used in combination, they may serve 
as data for monitoring purposes.   
       
1.6.1.1 Cost 
             Drug use can be expressed in terms of costs (e.g. national currency). 
Cost figures are suitable for an overall cost analysis of drug expenditure. Cost 
analysis is also applicable for prescription studies of only one substance. 
National and international comparisons based on cost parameters are often 
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misleading and are of limited value in the evaluation of drug use. Price 
differences between alternative preparations and different national cost levels 
often make evaluation difficult. Long-term studies are also difficult due to 
fluctuations in currency and prices. When cost data are used, the cheaper drugs 
may have little effect on the total levels, while the shift effect to more expensive 
drugs is more readily noticeable (WHO Collaborating Centre for Drug Statistics 
Methodology, 2005). 
 
1.6.1.2 Volume 
             Common physical units (e.g. gram, kilos, and liter), number of packages 
or tablets, and number of prescriptions are used in the calculation of the amount 
of drugs consumed. If consumption is given in terms of grams of an active 
ingredient, drugs with a lower potency will have a larger fraction of the total than 
drugs with a higher potency. 
             Counting the numbers of tablets also has disadvantages because the 
strength of the tablets may vary, resulting in outcomes that indicates low 
strength preparations contribute more than high strength preparations (WHO, 
2003). In contrast, the numbers of prescriptions do not give a good expression 
of total use, unless the total amounts of drugs per prescription are being 
considered. Counting prescriptions, however, is of great value in measuring the 
frequency of prescriptions and evaluating the clinical use of drugs (e.g. 
diagnosis and dosage used) (WHO Collaborating Centre for Drug Statistics 
Methodology, 2005). 
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1.6.1.3 Prescribed daily dose  
             The prescribed daily dose (PDD) is the average daily amount of drugs 
that are actually prescribed as obtained from a representative sample of 
prescriptions (WHO Collaborating Centre for Drug Statistics Methodology, 
2005). It can be calculated by getting information on the quantity dispensed, the 
strength and the number of days of supply. PDD should interpreted together 
with the diagnosis as the recommended dose may differ from one indication to 
another, or due to the severity of the illness. Furthermore, the dose may differ 
according to age, sex, as well as local and national therapy traditions. It should 
be noted that PDDs may differ from one country to another and even between 
regions or health facilities within the same country. So when making 
international comparisons this must be in considerations. When there is a 
substantial discrepancy between the PDD and the defined daily dose (DDD), it 
is important to consider this discrepancy when evaluating and interpretating 
drugs consumption figures.  
    
1.6.1.4 Defined daily dose  
             The defined daily dose (DDD) is a technical unit of drug consumption 
measurement as assigned by the WHO Collaborating Center for Drug Statistics 
Methodology (1993). It was developed to work with the Anatomical Therapeutic 
Chemical (ATC) Classification system in order to overcome objections against 
traditional units of measurement of drug consumption. The DDD for a given 
drug is the assumed average maintenance dose per day for a drug used for its 
main indication in an adult (WHO Collaborating Centre for Drug Statistics 
Methodology, 2005). DDD does not necessarily reflect the recommended, or 
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actual dose used, rather it is used as a measurement of drug utilization within, 
and across drug classes. It is also used when comparing drug utilization studies 
carried out at different locations and at different time periods. DDD is usually 
used expressed in DDD per thousand persons per day (DDD/ 1000/ day), and 
provides a rough estimate of consumption and not a real picture of actual use. 
For drugs used continuously, the number of DDDs gives a rough estimate of the 
numbers of its users. The DDD metric may not reflect the recommended or 
actual used dose (PDDs). Many drugs are for instance used in different dosage 
on different indications. The PDDs differ between countries, ethnic group and 
even between area or health facilities within same country.  Thus, it can be 
surmised that prescription data presented in DDDs will only provide a rough 
estimate of consumption and not a real picture of actual use. The other 
limitation of the DDD metric is that the DDDs for certain drugs have not been 
established. Examples of these drugs include preparations for topical use, IV 
solutions, sera, antineoplastic drugs, general and local anesthetics, and X-ray 
contrast media (WHO Collaborating Centre for Drug Statistics Methodology, 
2005).       
 
1.6.2 Anatomical Therapeutic Chemical  Index 
             The Anatomical Therapeutic Chemical (ATC) Index is an Anatomical 
Therapeutic Chemical classification system that assigns code letters and 
numbers to all drugs on an ATC basis (WHO Collaborating Centre for Drug 
Statistics Methodology, 2003). In the ATC system, the drugs are divided into 14 
different groups according to the organ and system on which they act, and their 
chemical, pharmacological, and main therapeutic use. There is only one ATC 
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Code for each pharmaceutical formulation and different ATC Codes are given 
for substances available in two different strengths or for formulations with 
clearly different uses. This system has been officially adopted by the Nordic 
countries and the WHO Drug Utilization Research Group (DURG), which has 
used it for a number of years (WHO, 2003). 
             No drug classification system is ideal from a combined epidemiological, 
clinical pharmacological, pharmaceutical, and chemical point of view. A drug 
may be used for a variety of clinical purposes and drugs of different structures 
may be used more or less for the same disease or symptom. Accordingly, 
pragmatic compromise solutions are to a certain extent necessary. Thus, when 
drug data are related to a specific area of use, reclassification may be helpful 
before interpretation. The ATC system is suitable for use in both manual and 
computerized systems. Table 1.4 below shows the ATC Code and the DDD of 
commonly used antiasthma drugs (Gislason et al., 1997). 
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Table 1.4: Defined daily doses (DDD) of commonly used antiasthma drugs 
Drug 
 
ATC code One DDD 
per mg 
Notes 
 β2-agonists    
Salbutamol inhaler R03AC02 0.8      Aerosol/ powder 
Terbutaline inhaler R03AC03 2.0      Aerosol/ powder 
Oral salbutamol R03CC02 12.0      Oral/ parenteral 
Oral terbutaline R03CC03 15.0      Oral/ parenteral 
Inhaled steroids    
Beclomethasone inhaler R03BA01 0.8      Aerosol/ powder 
Budesonide inhaler R03BA02 0.8      Aerosol/ powder 
Anticholinergics    
Ipratropium inhaler R03BB01 0.12      Aerosol/ powder 
Oxitropium inhaler R03BB02 0.6      Aerosol 
Theophylline R03DA04 400      Oral 
Cromoglycate inhaler   R03BC01 40.0      Aerosol/ powder 
Ketotifen R06Ax17 2.0      Oral 
     
 
1.7 Pharmacoeconomics 
             The rapid growth of health expenditure accompanied with limited 
resources has led to an increased interest in the economic evaluation of health 
care interventions. Most health care professionals especially pharmacists, are 
constantly faced with doing “more with less.” At the same time, they need to 
satisfy their patients health care demands based on their real needs and on 
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their wants. So pharmacoeconomics and outcome research must be a part of 
the background and expertise of many health professionals and pharmacists to 
enable them to allocate available resources according to priorities and to make 
choices between different pharmaceutical interventions. 
             Pharmacoeconomics analysis is defined as a tool to identify, measure, 
and compare cost and consequences (outcome) of pharmaceutical 
interventions with the aim of allocating health care resources and of optimizing 
patient outcomes for a given limited supply of resources (Bootman et al., 1991; 
Drummond et al., 1997). Costs are broadly classified as direct, indirect, and 
intangible costs. While outcomes are broadly categorized into economic, 
clinical, and humanistic outcomes (Reeder, 1995).   
The objectives of pharmacoeconomics are to: 
• optimize the patient’s outcomes with limited resources.  
• help in making critical decisions such as which drug should be in the 
health care formulary.  
• defining the best strategy for managing a particular disease through a 
creation of clinical guidelines for diagnosis and treatment.   
• help the policy maker and administrator to decide which services should 
be implemented within their organization 
• determine how health resources should be allocated 
• identify which of the series of alternative therapies will achieve the best 
cost effectiveness.   
• provide valuable information for health care decision makers    
             The common types of pharmacoeconomics studies are outlined in the 
following sections:  
